United States (US) based pharmaceutical major Johnson & Johnson (J&J) is working closely with Hyderabad based vaccine maker Biological E to facilitate the technology transfer for domestic manufacturing of its single-dose COVID-19 vaccine in India while it is expected that the vaccine's import into the country will begin by June-July, reports Livemint.
Sharing the development, secretary of the department of biotechnology Renu Swarup said that Biological E has an estimated capacity to produce as many as 600 million doses per annum.
The J&J vaccine (Ad26.COV2.S) leverages the adenovirus vector-based delivery system. It is said to be 67 per cent effective on average against moderate to severe/critical COVID-19 at least 14 days after administration, and 66 per cent effective at 28 days after vaccination.
Meanwhile, it should be noted that Swarup also said that Biological E is also working on its own vaccine candidate which has completed the trial stage.
Swarup further stated that the technology transfer for domestic manufacturing of the Russian Sputnik V vaccine is presently in process and that Indian production of the same will begin soon.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.